Cargando…
Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation
Recently, 2 small molecule kinase inhibitors (TKIs), targeting epidermal growth factor receptor (EGFR), have proven effective in the treatment of non-small cell lung cancer. However, it is unknown whether the EGFR double activating mutation of L858R in exon 21 and the in-frame deletion in exon 19 is...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919984/ https://www.ncbi.nlm.nih.gov/pubmed/20740181 http://dx.doi.org/10.1159/000310830 |
_version_ | 1782185226093461504 |
---|---|
author | Masago, Katsuhiro Togashi, Yosuke Fukudo, Masahide Terada, Tomohiro Irisa, Kaoru Sakamori, Yuichi Fujita, Shiro Kim, Young Hak Mio, Tadashi Inui, Ken-ichi Mishima, Michiaki |
author_facet | Masago, Katsuhiro Togashi, Yosuke Fukudo, Masahide Terada, Tomohiro Irisa, Kaoru Sakamori, Yuichi Fujita, Shiro Kim, Young Hak Mio, Tadashi Inui, Ken-ichi Mishima, Michiaki |
author_sort | Masago, Katsuhiro |
collection | PubMed |
description | Recently, 2 small molecule kinase inhibitors (TKIs), targeting epidermal growth factor receptor (EGFR), have proven effective in the treatment of non-small cell lung cancer. However, it is unknown whether the EGFR double activating mutation of L858R in exon 21 and the in-frame deletion in exon 19 is a predictor of the effectiveness of EGFR-TKIs. We report for the first time a case of non-small cell lung cancer with central nervous system metastases harboring a rare EGFR double activating mutation who showed a good clinical response to erlotinib, regardless of his poor performance status, as swallowing is not possible. Therefore, we suggest that erlotinib may become a therapeutic choice in cases of central nervous system metastases even with poor performance status. |
format | Text |
id | pubmed-2919984 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-29199842010-08-25 Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation Masago, Katsuhiro Togashi, Yosuke Fukudo, Masahide Terada, Tomohiro Irisa, Kaoru Sakamori, Yuichi Fujita, Shiro Kim, Young Hak Mio, Tadashi Inui, Ken-ichi Mishima, Michiaki Case Rep Oncol Published: April 2010 Recently, 2 small molecule kinase inhibitors (TKIs), targeting epidermal growth factor receptor (EGFR), have proven effective in the treatment of non-small cell lung cancer. However, it is unknown whether the EGFR double activating mutation of L858R in exon 21 and the in-frame deletion in exon 19 is a predictor of the effectiveness of EGFR-TKIs. We report for the first time a case of non-small cell lung cancer with central nervous system metastases harboring a rare EGFR double activating mutation who showed a good clinical response to erlotinib, regardless of his poor performance status, as swallowing is not possible. Therefore, we suggest that erlotinib may become a therapeutic choice in cases of central nervous system metastases even with poor performance status. S. Karger AG 2010-04-22 /pmc/articles/PMC2919984/ /pubmed/20740181 http://dx.doi.org/10.1159/000310830 Text en Copyright © 2010 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions. |
spellingShingle | Published: April 2010 Masago, Katsuhiro Togashi, Yosuke Fukudo, Masahide Terada, Tomohiro Irisa, Kaoru Sakamori, Yuichi Fujita, Shiro Kim, Young Hak Mio, Tadashi Inui, Ken-ichi Mishima, Michiaki Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation |
title | Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation |
title_full | Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation |
title_fullStr | Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation |
title_full_unstemmed | Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation |
title_short | Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation |
title_sort | good clinical response to erlotinib in a non-small cell lung cancer patient harboring multiple brain metastases and a double active somatic epidermal growth factor gene mutation |
topic | Published: April 2010 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919984/ https://www.ncbi.nlm.nih.gov/pubmed/20740181 http://dx.doi.org/10.1159/000310830 |
work_keys_str_mv | AT masagokatsuhiro goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation AT togashiyosuke goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation AT fukudomasahide goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation AT teradatomohiro goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation AT irisakaoru goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation AT sakamoriyuichi goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation AT fujitashiro goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation AT kimyounghak goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation AT miotadashi goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation AT inuikenichi goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation AT mishimamichiaki goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation |